STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1336 by analyst upside · 2026-06-27
PODD
Insulet Corporation
Healthcare · Market Cap $11B · P/E 36.0x
ANALYST PRICE TARGET
+51.8%
implied upside to consensus target
Current Price $158.25
Consensus Target $240.25
Bull Target $360.0
Bear Target $165.0
Analysts Covering 24
ANALYST CONSENSUS - BUY
Strong Buy
5
Buy
17
Hold
1
Sell
1
52-Week Low $138.79
52-Week High $354.88
YTD Return -44.1%
FUNDAMENTALS
Market Cap $11B
P/E Ratio (TTM) 36.0x
Forward P/E 19.6x
EPS (TTM) $4.40
PEG Ratio 1.31
Dividend Yield N/A
Revenue (TTM) $2.9B
Profit Margin 10.4%
52-WEEK RANGE
52-Week Low $138.79
52-Week High $354.88
Current Price $158.25
Bear Target $165.0
Bull Target $360.0
● Now $158.25 ● Target $240.25
TRADING DATA
Avg Volume 1.4M
YTD Return -44.1%
Analyst Count 24
Consensus Buy
Upside to Target +51.8%
Last Updated 2026-06-27

ANALYST SUMMARY

Insulet Corporation (PODD) is currently trading at $158.25 with a Wall Street consensus price target of $240.25, implying potential upside of 51.8% over the next 12 months. 24 analysts currently cover PODD, with a consensus rating of Buy - 92% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $360.0, while the most cautious has a target of $165.0.

PODD operates in the Healthcare sector with a market capitalisation of $11B. The stock is down 44.1% year-to-date and is currently trading near the lower end of its 52-week range of $138.79 – $354.88.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PODD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Truist Securities — Reiterated
Buy → Buy 2026-06-12 Building track record
Citigroup — Reiterated
Neutral → Neutral 2026-05-28 Building track record
RBC Capital reit
Outperform → Outperform 2026-05-27 Building track record
BTIG — Reiterated
Buy → Buy 2026-05-27 38% win rate (8 calls)
B of A Securities — Reiterated
Buy → Buy 2026-05-18 Building track record
Barclays — Reiterated
Underweight → Underweight 2026-05-08 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-05-07 Building track record
JP Morgan — Reiterated
Overweight → Overweight 2026-05-07 43% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
52
out of 100
Coverage depth
25/30
Consensus clarity
5/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →